3results about How to "Clinically convenient" patented technology

The present application provides a method for predicting the efficacy of umbilical cord blood natural killer cell treatment of neuroblastoma, belonging to the technical field of medical prediction and evaluation. The present application solves the clinical need for early and accurate prediction of the efficacy of immunotherapy for neuroblastoma. The method comprises: obtaining peripheral blood test data of a neuroblastoma patient before multiple reinfusion treatment nodes of umbilical cord blood natural killer cell treatment; based on the processed node-level peripheral blood test data, at least one dynamic linkage feature reflecting the dynamic linkage relationship of the indicators in the patient's body is calculated; at least one static feature index is obtained; the dynamic linkage feature and the static feature index are input into a pre-trained efficacy prediction model to obtain the response probability of the patient to umbilical cord blood natural killer cell immunotherapy. The present application accurately predicts the efficacy of umbilical cord blood natural killer cell treatment of neuroblastoma by analyzing the peripheral blood test data of the patient at multiple time points and constructing dynamic linkage features.

The application relates to the technical field of oral cavity expansion, in particular to an expansion device for oral cavity treatment, which comprises an expansion forceps, a self-adaptive supporting mechanism and an expansion maintaining assembly. The expansion forceps is opened by applying force to the forceps body, so that the forceps body is in contact with the mouth and the expansion of the mouth is realized. The self-adaptive supporting mechanism is installed on one side of the bottom of the expansion forceps. When the self-adaptive supporting mechanism is pressed, the supporting mechanism can be supported on the cheek area of the mouth. When the expansion forceps is expanded by applying force, the expansion maintaining assembly is locked by a one-way locking structure, so that the expansion forceps cannot be restored due to the force applied by the mouth after being opened. The operation is convenient, and the hands of the doctor are freed. The supporting feet of the self-adaptive supporting mechanism can automatically adhere to the cheek area of the patient and be locked and positioned by gravity self-falling design, so that the doctor does not need to continuously hold and fix. The one-way locking structure of the expansion maintaining assembly is matched, so that the opening state can be stably maintained after expansion without continuously applying a pushing force, the doctor can focus on the treatment operation, and the diagnosis and treatment efficiency is remarkably improved.

The invention relates to the technical field of medicines, in particular to a pharmaceutical composition of a paclitaxel conjugate, which comprises paclitaxel, a paclitaxel analogue or a conjugate thereof, an organic solvent; a solubilizer; and, a pH regulator. The conjugate is ANG1005, the solubilizer comprises mPEG-DSPE, in the mPEG-DSPE, the molecular weight of PEG is 500-10000, the molecular weight of PEG is 500-10000, and in the mPEG-DSPE, the molecular weight of PEG is 500-1000. The weight ratio of the mPEG-DSPE to the ANG1005 is (3 to 15): 1. According to the preparation method, the active substance solution and the solubilizer solution are prepared respectively, and then the two solutions are mixed together, so that the prepared solution is good in physical stability. When the ANG1005 freeze-drying agent prepared by the invention is redissolved, only normal saline is needed as a redissolving agent, the clarification of the redissolving solution can be realized within 5 minutes, and the clinical use is more convenient; the osmotic pressure of the freeze-drying agent after redissolution is lower than that of an ANG1005 freeze-drying agent in the prior art; meanwhile, in the in-vivo metabolism process of the freeze-drying agent (redissolving solution), ANG1005 is higher in chemical stability and not prone to hydrolysis, paclitaxel released in blood is less, and side effects on the human body are smaller.